Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy

doi:10.5306/wjco.v7.i5.387

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7385)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

624

WORD

253

HTML

3941

Tables (1-5)

219

Sum=5037

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

874

Download

1474

Sum=2348

Oct 10, 2016 (publication date) through Apr 28, 2024

Times Cited of This Article

Times Cited (38)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Clin Oncol. Oct 10, 2016; 7(5): 387-394
Published online Oct 10, 2016. doi: 10.5306/wjco.v7.i5.387

Table 1 Clinical and pathological general features

Features	n = 98 (%)
Median age	49 ± 9
Clinical stage
II	13 (13.3)
III	85 (86.73)
Histologic grade
II	23 (23.5)
III	74 (75.5)
Subtype histologic
Ductal	95 (96.9)
Lobular	2 (2.1)
Neoadjuvant chemotherapy
AC	9 (9.2)
AC-Taxane	86 (87.7)
Taxane alone	3 (3.1)
Surgery
Tumorectomy	29 (29.6)
Mastectomy	65 (66.3)
Unknown	4 (4.1)
Inflammatory
No	69 (70.4)
Yes	29 (29.6)
pCR
No	69 (70.4)
Yes	29 (29.6)
Recurrence
No	56 (57.1)
Yes	42 (42.9)
Death
No	53 (54.1)
Yes	45 (45.9)

AC: Adriamycin/cyclophosphamide; AC-Taxane: Adriamycin/cyclophosphamide, followed by treatment with taxane; pCR: Pathologic complete response.

Citation: Castaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C, Dolores-Cerna K, Belmar-Lopez C, Abugattas J, Calderon G, De La Cruz M, Cotrina M, Dunstan J, Gomez HL, Vidaurre T. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol 2016; 7(5): 387-394
URL: https://www.wjgnet.com/2218-4333/full/v7/i5/387.htm
DOI: https://dx.doi.org/10.5306/wjco.v7.i5.387